| Year |
Citation |
Score |
| 2023 |
Landberg N, Köhnke T, Feng Y, Nakauchi Y, Fan AC, Linde MH, Karigane D, Lim K, Sinha R, Malcovati L, Thomas D, Majeti R. IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation. Blood Cancer Discovery. PMID 38091010 DOI: 10.1158/2643-3230.BCD-23-0195 |
0.495 |
|
| 2023 |
Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, Volkmer JP, Chen JY, Stanger AMP, Lehmann A, Appiah B, Märklin M, Rücker-Braun E, Salih HR, Roerden M, ... ... Majeti R, et al. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood Cancer Discovery. OF1-OF22. PMID 37847741 DOI: 10.1158/2643-3230.BCD-23-0020 |
0.639 |
|
| 2023 |
Sayitoglu EC, Luca BA, Boss AP, Thomas BC, Freeborn RA, Uyeda MJ, Chen PP, Nakauchi Y, Waichler C, Lacayo N, Bacchetta R, Majeti R, Gentles AJ, Cepika AM, Roncarolo MG. AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML. Biorxiv : the Preprint Server For Biology. PMID 37790561 DOI: 10.1101/2023.09.21.558911 |
0.328 |
|
| 2023 |
Fan AC, Nakauchi Y, Bai L, Azizi A, Nuno KA, Zhao F, Köhnke T, Karigane D, Cruz-Hernandez D, Reinisch A, Khatri P, Majeti R. RUNX1 loss renders hematopoietic and leukemic cells dependent on interleukin-3 and sensitive to JAK inhibition. The Journal of Clinical Investigation. PMID 37581927 DOI: 10.1172/JCI167053 |
0.776 |
|
| 2023 |
Kotini AG, Carcamo S, Cruz-Rodriguez N, Olszewska M, Wang T, Demircioglu D, Chang CJ, Bernard E, Chao MP, Majeti R, Luo H, Kharas MG, Hasson D, Papapetrou EP. Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia. Blood Cancer Discovery. OF1-OF18. PMID 37067914 DOI: 10.1158/2643-3230.BCD-22-0167 |
0.716 |
|
| 2023 |
Sconocchia T, Foßelteder J, Köhnke T, Majeti R, Reinisch A. Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells. Journal of Visualized Experiments : Jove. PMID 36971438 DOI: 10.3791/64558 |
0.623 |
|
| 2023 |
Linde MH, Fan AC, Kohnke T, Trotman-Grant AC, Gurev SF, Phan P, Zhao F, Haddock NL, Nuno KA, Gars EJ, Stafford M, Marshall PL, Dove CG, Linde IL, Landberg N, ... ... Majeti R, et al. Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy. Cancer Discovery. PMID 36856575 DOI: 10.1158/2159-8290.CD-21-0502 |
0.7 |
|
| 2022 |
Thomas D, Wu M, Nakauchi Y, Zheng M, Thompson-Peach CA, Lim K, Landberg N, Köhnke T, Robinson N, Kaur S, Kutyna M, Stafford M, Hiwase D, Reinisch A, Peltz G, ... Majeti R, et al. Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery. PMID 36355448 DOI: 10.1158/2159-8290.CD-21-0218 |
0.684 |
|
| 2022 |
Chen J, Johnson L, McKenna K, Choi T, Duan J, Feng D, Tsai J, Garcia-Martin N, Sompalli K, Maute R, Vyas P, Majeti R, Takimoto C, Liu J, Ramsingh G, et al. MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS). Clinical Lymphoma, Myeloma & Leukemia. S317-S318. PMID 36163968 DOI: 10.1016/S2152-2650(22)01421-5 |
0.837 |
|
| 2022 |
Bassal MA, Samaraweera SE, Lim K, Benard BA, Bailey S, Kaur S, Leo P, Toubia J, Thompson-Peach C, Nguyen T, Maung KZY, Casolari DA, Iarossi DG, Pagani IS, Powell J, ... ... Majeti R, et al. Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications. 13: 4131. PMID 35840577 DOI: 10.1038/s41467-022-31952-7 |
0.397 |
|
| 2022 |
Bassal MA, Samaraweera SE, Lim K, Bernard BA, Bailey S, Kaur S, Leo P, Toubia J, Thompson-Peach C, Nguyen T, Maung KZY, Casolari DA, Iarossi DG, Pagani IS, Powell J, ... ... Majeti R, et al. Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications. 13: 2614. PMID 35551192 DOI: 10.1038/s41467-022-30223-9 |
0.429 |
|
| 2022 |
Nakauchi Y, Azizi A, Thomas D, Corces MR, Reinisch A, Sharma R, Cruz Hernandez D, Kohnke T, Karigane D, Fan A, Martinez-Krams D, Stafford M, Kaur S, Dutta R, Phan P, ... ... Majeti R, et al. The cell type specific 5hmC landscape and dynamics of healthy human hematopoiesis and TET2-mutant pre-leukemia. Blood Cancer Discovery. PMID 35532363 DOI: 10.1158/2643-3230.BCD-21-0143 |
0.799 |
|
| 2022 |
Theruvath J, Menard M, Smith BAH, Linde MH, Coles GL, Dalton GN, Wu W, Kiru L, Delaidelli A, Sotillo E, Silberstein JL, Geraghty AC, Banuelos A, Radosevich MT, Dhingra S, ... ... Majeti R, et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nature Medicine. PMID 35027753 DOI: 10.1038/s41591-021-01625-x |
0.822 |
|
| 2021 |
Benard BA, Leak LB, Azizi A, Thomas D, Gentles AJ, Majeti R. Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia. Nature Communications. 12: 7244. PMID 34903734 DOI: 10.1038/s41467-021-27472-5 |
0.433 |
|
| 2021 |
Richards RM, Zhao F, Freitas KA, Parker KR, Xu P, Fan A, Sotillo E, Daugaard M, Oo HZ, Liu J, Hong WJ, Sorensen PH, Chang HY, Satpathy AT, Majzner RG, ... Majeti R, et al. NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. Blood Cancer Discovery. 2: 648-665. PMID 34778803 DOI: 10.1158/2643-3230.BCD-20-0208 |
0.772 |
|
| 2020 |
Mantri S, Reinisch A, Dejene BT, Lyell DJ, DiGiusto DL, Agarwal-Hashmi R, Majeti R, Weinberg KI, Porteus MH. CD34 expression does not correlate with immunophenotypic stem cell or progenitor content in human cord blood products. Blood Advances. 4: 5357-5361. PMID 33136125 DOI: 10.1182/bloodadvances.2020002891 |
0.682 |
|
| 2020 |
Nishimura T, Xu H, Iwasaki M, Karigane D, Saavedra B, Takahashi Y, Suchy FP, Monobe S, Martin RM, Ohtaka M, Nakanishi M, Burrows SR, Cleary ML, Majeti R, Shibuya A, et al. Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cells. Gene Therapy. PMID 32704085 DOI: 10.1038/S41434-020-0179-Z |
0.395 |
|
| 2020 |
Liu J, Xavy S, Mihardja S, Chen S, Sompalli K, Feng D, Choi TS, Agoram B, Majeti R, Weissman IL, Volkmer JP. Targeting macrophage checkpoint inhibitor SIRPa for anticancer therapy. Jci Insight. PMID 32427583 DOI: 10.1172/Jci.Insight.134728 |
0.572 |
|
| 2020 |
Zhang TY, Dutta R, Benard B, Zhao F, Yin R, Majeti R. IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia. Science Translational Medicine. 12. PMID 32269167 DOI: 10.1126/Scitranslmed.Aax5104 |
0.361 |
|
| 2020 |
Ediriwickrema A, Aleshin A, Reiter JG, Corces MR, Köhnke T, Stafford M, Liedtke M, Medeiros BC, Majeti R. Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Advances. 4: 943-952. PMID 32150611 DOI: 10.1182/Bloodadvances.2019001181 |
0.39 |
|
| 2020 |
Koldobskiy MA, Abante J, Jenkinson G, Pujadas E, Tetens A, Zhao F, Tryggvadottir R, Idrizi A, Reinisch A, Majeti R, Goutsias J, Feinberg AP. A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML. Epigenetics. 1-18. PMID 32114880 DOI: 10.1080/15592294.2020.1734149 |
0.618 |
|
| 2020 |
Dutta R, Zhang TY, Köhnke T, Thomas D, Linde M, Gars E, Stafford M, Kaur S, Nakauchi Y, Yin R, Azizi A, Narla A, Majeti R. Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2. The Journal of Clinical Investigation. PMID 31895700 DOI: 10.1172/Jci133344 |
0.579 |
|
| 2020 |
Ediriwickrema A, Ramakrishnan S, Nakamoto M, Ghanekar S, Luca B, Newman A, Gentles A, Majeti R. Abstract 3779: Multiomic single cell analysis of normal human bone marrow identifies a unique stem and progenitor population that expands in AML Cancer Research. 80: 3779-3779. DOI: 10.1158/1538-7445.Am2020-3779 |
0.41 |
|
| 2019 |
Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer JP, Weissman IL, Majeti R. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Frontiers in Oncology. 9: 1380. PMID 32038992 DOI: 10.3389/Fonc.2019.01380 |
0.836 |
|
| 2019 |
Nishimura T, Hsu I, Martinez-Krams DC, Nakauchi Y, Majeti R, Yamazaki S, Nakauchi H, Wilkinson AC. Use of polyvinyl alcohol for chimeric antigen receptor T-cell expansion. Experimental Hematology. PMID 31874780 DOI: 10.1016/J.Exphem.2019.11.007 |
0.36 |
|
| 2019 |
Granja JM, Klemm S, McGinnis LM, Kathiria AS, Mezger A, Corces MR, Parks B, Gars E, Liedtke M, Zheng GXY, Chang HY, Majeti R, Greenleaf WJ. Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. Nature Biotechnology. PMID 31792411 DOI: 10.1038/S41587-019-0332-7 |
0.551 |
|
| 2019 |
Guan Y, Chen X, Wu M, Zhu W, Arslan A, Takeda S, Nguyen MH, Majeti R, Thomas D, Zheng M, Peltz G. The Phosphatidylethanolamine Biosynthesis Pathway Provides a New Target for Cancer Chemotherapy. Journal of Hepatology. PMID 31760071 DOI: 10.1016/J.Jhep.2019.11.007 |
0.445 |
|
| 2019 |
Li Y, Thomas D, Deutzmann A, Majeti R, Felsher DW, Dill DL. Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Scientific Reports. 9: 16775. PMID 31727951 DOI: 10.1038/S41598-019-53290-3 |
0.585 |
|
| 2019 |
Xu J, Nuno K, Litzenburger UM, Qi Y, Corces MR, Majeti R, Chang HY. Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA. Elife. 8. PMID 30958261 DOI: 10.7554/Elife.45105 |
0.543 |
|
| 2019 |
Thomas R, Majeti R. No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML. Cancer Cell. 35: 337-339. PMID 30889374 DOI: 10.1016/J.Ccell.2019.02.013 |
0.373 |
|
| 2019 |
Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, ... ... Majeti R, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802018. PMID 30811285 DOI: 10.1200/Jco.18.02018 |
0.801 |
|
| 2019 |
Benard B, Gentles AJ, Köhnke T, Majeti R, Thomas D. Data mining for mutation-specific targets in acute myeloid leukemia. Leukemia. PMID 30728456 DOI: 10.1038/S41375-019-0387-Y |
0.521 |
|
| 2019 |
Takimoto CH, Chao MP, Gibbs C, McCamish MA, Liu J, Chen JY, Majeti R, Weissman IL. The Macrophage "Do not Eat Me" Signal, CD47, Is A Clinically Validated Cancer Immunotherapy Target. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30689700 DOI: 10.1093/Annonc/Mdz006 |
0.649 |
|
| 2019 |
Chao MP, Majeti R. Induced pluripotent stem cell modeling of malignant hematopoiesis. Experimental Hematology. PMID 30659850 DOI: 10.1016/J.Exphem.2019.01.002 |
0.712 |
|
| 2019 |
Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, ... ... Majeti R, et al. CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30655315 DOI: 10.1158/1078-0432.Ccr-18-0432 |
0.407 |
|
| 2019 |
Saygin C, Matei D, Majeti R, Reizes O, Lathia JD. Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell Stem Cell. 24: 25-40. PMID 30595497 DOI: 10.1016/J.Stem.2018.11.017 |
0.395 |
|
| 2019 |
Xu J, Nuno K, Litzenburger UM, Qi Y, Corces MR, Majeti R, Chang HY. Author response: Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA Elife. DOI: 10.7554/Elife.45105.033 |
0.483 |
|
| 2019 |
Linde MH, Dove CG, Gurev SF, Phan P, Zhao F, Miller LP, Majeti R. Reprogramming Leukemia Cells into Antigen Presenting Cells As a Novel Cancer Vaccination Immunotherapy Blood. 134: 3217-3217. DOI: 10.1182/Blood-2019-128577 |
0.353 |
|
| 2019 |
Dutta R, Zhang TY, Koehnke T, Thomas D, Gars E, Stafford M, Nakauchi Y, Kaur S, Yin R, Narla A, Majeti R. Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2 Blood. 134: 540-540. DOI: 10.1182/Blood-2019-124551 |
0.482 |
|
| 2019 |
Aleshin A, Durruthy-Durruthy R, Corces R, Liedtke M, Eastburn D, Majeti R. Abstract 5130: Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection Cancer Research. 79: 5130-5130. DOI: 10.1158/1538-7445.Am2019-5130 |
0.777 |
|
| 2018 |
Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Majeti R, Babon JJ, et al. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances. 4: eaat3834. PMID 30498775 DOI: 10.1126/Sciadv.Aat3834 |
0.479 |
|
| 2018 |
Bak RO, Dever DP, Reinisch A, Cruz Hernandez D, Majeti R, Porteus MH. Correction: Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. Elife. 7. PMID 30444489 DOI: 10.7554/eLife.43690 |
0.623 |
|
| 2018 |
Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, ... ... Majeti R, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine. 379: 1711-1721. PMID 30380386 DOI: 10.1056/Nejmoa1807315 |
0.808 |
|
| 2018 |
Chan CKF, Gulati GS, Sinha R, Tompkins JV, Lopez M, Carter AC, Ransom RC, Reinisch A, Wearda T, Murphy M, Brewer RE, Koepke LS, Marecic O, Manjunath A, Seo EY, ... ... Majeti R, et al. Identification of the Human Skeletal Stem Cell. Cell. 175: 43-56.e21. PMID 30241615 DOI: 10.1016/J.Cell.2018.07.029 |
0.806 |
|
| 2018 |
Buenrostro JD, Corces MR, Lareau CA, Wu B, Schep AN, Aryee MJ, Majeti R, Chang HY, Greenleaf WJ. Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation. Cell. PMID 29706549 DOI: 10.1016/J.Cell.2018.03.074 |
0.566 |
|
| 2018 |
Sikic BI, Lakhani NJ, Patnaik A, Shah S, Chandana SR, Rasco DW, Colevas AD, O'Rourke TJ, Papadopoulos KP, Fisher GA, Chao M, Agoram B, Chen JY, Huang J, Axt M, ... Majeti R, et al. A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors. Journal of Clinical Oncology. 36: 3002-3002. DOI: 10.1200/Jco.2018.36.15_Suppl.3002 |
0.806 |
|
| 2018 |
Zhang TY, Dutta R, Zhao F, Majeti R. Human Acute Myeloid Leukemia Inhibits Normal Erythroid Differentiation through the Paracrine Effects of IL-6 Blood. 132: 911-911. DOI: 10.1182/Blood-2018-99-119297 |
0.302 |
|
| 2018 |
Aleshin A, Durruthy-Durruthy R, Corces MR, Stafford M, Liedtke M, Medeiros BC, Eastburn DJ, Majeti R. Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse Blood. 132: 1469-1469. DOI: 10.1182/Blood-2018-99-118089 |
0.385 |
|
| 2018 |
Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Babon JJ, Majeti R, et al. Accumulation of JAK Activation-Loop Phosphorylation Promotes Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis Blood. 132: 1787-1787. DOI: 10.1182/Blood-2018-99-115760 |
0.429 |
|
| 2018 |
Chen JY, McKenna KM, Choi TS, Duan J, Brown L, Stewart JJ, Sompalli K, Vyas P, Schrier S, Majeti R, Weissman IL, Elrod K, Chao MP, Takimoto CH, Liu J, et al. RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9 Blood. 132: 2327-2327. DOI: 10.1182/Blood-2018-99-115674 |
0.614 |
|
| 2018 |
Thomas D, Nakauchi Y, Wu M, Zheng M, Sinha S, Dill D, Peltz G, Majeti R. IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML Blood. 132: 440-440. DOI: 10.1182/Blood-2018-99-115040 |
0.54 |
|
| 2018 |
Nakauchi Y, Thomas D, Sharma R, Corces MR, Reinisch A, Cruz D, Koehnke T, Karigane D, Fan A, Majeti R. Azacitidine and Ascorbate Inhibit the Competitive Outgrowth of Human TET2 Mutant HSPCs in a Xenograft Model of Pre-Leukemia Blood. 132: 887-887. DOI: 10.1182/Blood-2018-99-113907 |
0.774 |
|
| 2018 |
Fan A, Reinisch A, Majeti R. Cell Autonomous and Non-Autonomous Effects of RUNX1 Deficiency in Inherited AML Predisposition Syndromes Experimental Hematology. 64: S64. DOI: 10.1016/J.Exphem.2018.06.221 |
0.638 |
|
| 2017 |
Karamitros D, Stoilova B, Aboukhalil Z, Hamey F, Reinisch A, Samitsch M, Quek L, Otto G, Repapi E, Doondeea J, Usukhbayar B, Calvo J, Taylor S, Goardon N, Six E, ... ... Majeti R, et al. Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells. Nature Immunology. PMID 29167569 DOI: 10.1038/S41590-017-0001-2 |
0.695 |
|
| 2017 |
Corces MR, Chang HY, Majeti R. Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. Frontiers in Oncology. 7: 263. PMID 29164062 DOI: 10.3389/Fonc.2017.00263 |
0.589 |
|
| 2017 |
Bak RO, Dever DP, Reinisch A, Cruz Hernandez D, Majeti R, Porteus MH. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. Elife. 6. PMID 28956530 DOI: 10.7554/Elife.27873 |
0.683 |
|
| 2017 |
Reinisch A, Hernandez DC, Schallmoser K, Majeti R. Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice. Nature Protocols. 12: 2169-2188. PMID 28933777 DOI: 10.1038/Nprot.2017.088 |
0.686 |
|
| 2017 |
McKeown MR, Corces MR, Eaton ML, Fiore C, Lee E, Lopez JT, Chen MW, Smith D, Chan SM, Koenig JL, Austgen K, Guenther MG, Orlando DA, Lovén J, Fritz CC, ... Majeti R, et al. Super-Enhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. Cancer Discovery. PMID 28729405 DOI: 10.1158/2159-8290.Cd-17-0399 |
0.599 |
|
| 2017 |
Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernards R, Majeti R, Dill DL. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications. 8: 15580. PMID 28561042 DOI: 10.1038/Ncomms15580 |
0.764 |
|
| 2017 |
Thomas D, Majeti R. Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models. Cancer Discovery. 7: 459-461. PMID 28461409 DOI: 10.1158/2159-8290.Cd-17-0270 |
0.498 |
|
| 2017 |
Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. PMID 28159741 DOI: 10.1182/Blood-2016-10-696054 |
0.599 |
|
| 2017 |
Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Bernards R, Majeti R, Dill DL. Abstract A27: Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer primary tumor data Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A27 |
0.789 |
|
| 2017 |
Fiore CM, McKeown MR, Lee E, Eaton ML, Smith D, Austgen K, Chen MW, Guenther M, Corces MR, Majeti R, Olson E, Fritz CC. Abstract PR05: SY-1425 (tamibarotene), a potent and selective RARα agonist, induces changes in the transcriptional regulatory circuit of AML cells leading to differentiation Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Hemmal17-Pr05 |
0.434 |
|
| 2017 |
McKeown MR, Eaton ML, Fiore C, Lee E, Austgen K, Smith D, Corces MR, Majeti R, Fritz CC. Abstract 1511: AML patient clustering by super-enhancers reveals an RARA associated transcription factor signaling partner Cancer Research. 77: 1511-1511. DOI: 10.1158/1538-7445.Am2017-1511 |
0.359 |
|
| 2017 |
Sikic BI, Padda SK, Shah SA, Colevas AD, Narayanan S, Fisher GA, Supan D, Wakelee HA, Aoki R, Pegram MD, Villalobos VM, Liu J, Takimoto C, Chao MP, Volkmer JP, ... Majeti R, et al. SC14.04 The CD47 Macrophage Checkpoint as a New Immunotherapy Target Journal of Thoracic Oncology. 12: S108-S109. DOI: 10.1016/J.Jtho.2016.11.094 |
0.541 |
|
| 2017 |
Stoilova B, Karamitros D, Aboukhalil Z, Reinisch A, Hamey F, Samitsch M, Quek L, Otto G, Repapi E, Doondeea J, Usukhbayar B, Calvo J, Taylor S, Goardon N, Six E, ... ... Majeti R, et al. Single cell assays unveil functional and transcriptional heterogeneity of human hemopoietic lympho-myeloid progenitors Experimental Hematology. 53: S50. DOI: 10.1016/J.Exphem.2017.06.074 |
0.668 |
|
| 2016 |
Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, Xavy S, Shen J, Haag D, Chanda S, Sinha R, Morganti RM, Nishimura T, Ameen M, Wu H, ... ... Majeti R, et al. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell. PMID 28089908 DOI: 10.1016/J.Stem.2016.11.018 |
0.801 |
|
| 2016 |
Reinisch A, Majeti R. Sticking It to the Niche: CD98 Mediates Critical Adhesive Signals in AML. Cancer Cell. 30: 662-664. PMID 27846387 DOI: 10.1016/J.Ccell.2016.10.014 |
0.748 |
|
| 2016 |
Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. PMID 27820943 DOI: 10.1038/Nature20134 |
0.776 |
|
| 2016 |
Mazumdar C, Majeti R. The role of mutations in the cohesin complex in acute myeloid leukemia. International Journal of Hematology. PMID 27796738 DOI: 10.1007/S12185-016-2119-7 |
0.416 |
|
| 2016 |
Huang M, Garcia JS, Thomas D, Zhu L, Nguyen LX, Chan SM, Majeti R, Medeiros BC, Mitchell BS. Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget. PMID 27732946 DOI: 10.18632/Oncotarget.12493 |
0.648 |
|
| 2016 |
Corces MR, Buenrostro JD, Wu B, Greenside PG, Chan SM, Koenig JL, Snyder MP, Pritchard JK, Kundaje A, Greenleaf WJ, Majeti R, Chang HY. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nature Genetics. PMID 27526324 DOI: 10.1038/Ng.3646 |
0.716 |
|
| 2016 |
Jonas BA, Johnson C, Gratzinger D, Majeti R. Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. Plos One. 11: e0159189. PMID 27428079 DOI: 10.1371/Journal.Pone.0159189 |
0.64 |
|
| 2016 |
Thomas D, Majeti R. Burning Fat Fuels Leukemic Stem Cell Heterogeneity. Cell Stem Cell. 19: 1-2. PMID 27392217 DOI: 10.1016/J.Stem.2016.06.014 |
0.559 |
|
| 2016 |
Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, ... ... Majeti R, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of Clinical Investigation. PMID 27294525 DOI: 10.1172/Jci81603 |
0.832 |
|
| 2016 |
Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, Schallmoser K, Strunk D, Majeti R. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nature Medicine. PMID 27213817 DOI: 10.1038/Nm.4103 |
0.727 |
|
| 2016 |
Zhu L, Li Q, Wong SH, Huang M, Klein BJ, Shen J, Ikenouye L, Onishi M, Schneidawind D, Buechele C, Hansen L, Duque-Afonso J, Zhu F, Mas Martin G, Gozani O, ... Majeti R, et al. ASH1L links histone H3 lysine 36 di-methylation to MLL leukemia. Cancer Discovery. PMID 27154821 DOI: 10.1158/2159-8290.Cd-16-0058 |
0.604 |
|
| 2016 |
Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, Majeti R. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27126995 DOI: 10.1158/1078-0432.Ccr-15-2503 |
0.761 |
|
| 2016 |
Chao MP, McKenna KM, Cha A, Feng D, Liu J, Sikic BI, Majeti R, Weissman IL, Takimoto C, Volkmer J. Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Pr13 |
0.831 |
|
| 2016 |
Bak RO, Dever DP, Saxena N, Camarena J, Reinisch A, Wilkens AB, Nicolas CE, Hendel A, Majeti R, Weinberg KI, Porteus MH. 43. CRISPR/Cas9 and rAAV6-Mediated Targeted Integration at the CCR5 Locus in Hematopoietic Stem and Progenitor Cells Molecular Therapy. 24: S19. DOI: 10.1016/S1525-0016(16)32852-0 |
0.707 |
|
| 2016 |
Dever DP, Bak RO, Camarena J, Saxena N, Reinisch A, Nicolas CE, Wilkens AB, Hendel A, Uchida N, Majeti R, Weinberg KI, Porteus MH. 39. FACS-Based Enrichment of a Highly Purified HBB-Targeted Hematopoietic Stem and Progenitor Cell Population Using rAAV6 and CRISPR/Cas9 Molecular Therapy. 24: S17. DOI: 10.1016/S1525-0016(16)32848-9 |
0.818 |
|
| 2016 |
Porteus M, Bak R, Dever D, Hendel A, Reinisch A, Majeti R. Genome editing by homologous recombination of human hematopoietic stem cells Experimental Hematology. 44: S26. DOI: 10.1016/J.Exphem.2016.06.014 |
0.665 |
|
| 2015 |
Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces MR, Flynn RA, Buenrostro JD, Chan SM, Thomas D, Koenig JL, Hong WJ, Chang HY, Majeti R. Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell. PMID 26607380 DOI: 10.1182/Blood.V126.23.841.841 |
0.799 |
|
| 2015 |
Sykes SM, Kokkaliaris KD, Milsom MD, Levine RL, Majeti R. Clonal Evolution of Preleukemic hematopoietic stem cells in acute myeloid leukemia. Experimental Hematology. PMID 26455528 DOI: 10.1016/J.Exphem.2015.08.012 |
0.436 |
|
| 2015 |
Jung N, Dai B, Gentles AJ, Majeti R, Feinberg AP. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nature Communications. 6: 8489. PMID 26444494 DOI: 10.1038/Ncomms9489 |
0.385 |
|
| 2015 |
Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. Plos One. 10: e0137345. PMID 26390038 DOI: 10.1371/Journal.Pone.0137345 |
0.804 |
|
| 2015 |
Reinisch A, Chan SM, Thomas D, Majeti R. Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Seminars in Hematology. 52: 150-64. PMID 26111462 DOI: 10.1053/J.Seminhematol.2015.03.008 |
0.795 |
|
| 2015 |
Piccione EC, Juarez S, Liu J, Tseng S, Ryan C, Narayanan C, Wang L, Weiskopf K, Majeti R. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. Mabs. 0. PMID 26083076 DOI: 10.1080/19420862.2015.1062192 |
0.766 |
|
| 2015 |
McClellan JS, Dove C, Gentles AJ, Ryan CE, Majeti R. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. Proceedings of the National Academy of Sciences of the United States of America. 112: 4074-9. PMID 25775523 DOI: 10.1073/Pnas.1413383112 |
0.457 |
|
| 2015 |
Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo I, Weissman IL, Minary P, ... Majeti R, et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell. 160: 1196-208. PMID 25728669 DOI: 10.1016/J.Cell.2015.02.011 |
0.415 |
|
| 2015 |
Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, Majeti R. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine. 21: 178-84. PMID 25599133 DOI: 10.1038/Nm.3788 |
0.665 |
|
| 2015 |
Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, ... ... Majeti R, et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood. 125: 249-60. PMID 25406351 DOI: 10.1182/Blood-2014-04-572255 |
0.814 |
|
| 2015 |
Sinha S, Thomas D, Yu L, Gentles AJ, Jung N, Corces-Zimmerman MR, Chan SM, Reinisch A, Feinberg AP, Dill DL, Majeti R. Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood. 125: 316-26. PMID 25398938 DOI: 10.1182/Blood-2014-03-566018 |
0.772 |
|
| 2015 |
Chao MP, Hong J, Kunder C, Lester L, Schrier SL, Majeti R. Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab. American Journal of Hematology. 90: 78-81. PMID 24942207 DOI: 10.1002/Ajh.23791 |
0.645 |
|
| 2015 |
Sinha S, Thomas D, Majeti R, Dill DL. Abstract A1-23: Deciphering the cancer methylome with Boolean implications to find novel drivers of aberrant DNA methylation and actionable drug targets Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-B2-20 |
0.517 |
|
| 2015 |
Eaton M, Corces-Zimmerman R, Lopez J, Fritz C, Olson E, Majeti R, Loven J. Abstract 2212: Super-enhancer landscapes specify molecular subtypes and novel targets in acute myeloid leukemia Cancer Research. 75: 2212-2212. DOI: 10.1158/1538-7445.Am2015-2212 |
0.422 |
|
| 2015 |
Sinha S, Thomas D, Gao Y, Chan SM, Brunen D, Bernards R, Majeti R, Dill DL. Abstract LB-B07: MiSL: a method for mining synthetic lethal partners of somatic mutations identifies acetyl-CoA carboxylase as a synthetic lethal interactor of the IDH1 mutation in Leukemia Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-B07 |
0.675 |
|
| 2014 |
Majeti R. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia. Best Practice & Research. Clinical Haematology. 27: 229-34. PMID 25455271 DOI: 10.1016/J.Beha.2014.10.003 |
0.443 |
|
| 2014 |
Corces-Zimmerman MR, Majeti R. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia. 28: 2276-82. PMID 25005245 DOI: 10.1038/Leu.2014.211 |
0.471 |
|
| 2014 |
Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, ... ... Majeti R, et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications. 5: 3904. PMID 24887457 DOI: 10.1038/Ncomms4904 |
0.393 |
|
| 2014 |
Nguyen le XT, Chan SM, Ngo TD, Raval A, Kim KK, Majeti R, Mitchell BS. Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells. Blood. 124: 579-89. PMID 24850755 DOI: 10.1182/Blood-2013-12-544726 |
0.555 |
|
| 2014 |
Lee JY, Hong WJ, Majeti R, Stearns T. Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms. Plos One. 9: e92641. PMID 24658090 DOI: 10.1371/Journal.Pone.0092641 |
0.301 |
|
| 2014 |
Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceedings of the National Academy of Sciences of the United States of America. 111: 2548-53. PMID 24550281 DOI: 10.1073/Pnas.1324297111 |
0.572 |
|
| 2014 |
Thomas D, Sinha S, Yu L, Jung N, Dai B, Gentles AJ, Feinberg AP, Dill D, Majeti R. Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition Blood. 124: 780-780. DOI: 10.1182/Blood.V124.21.780.780 |
0.604 |
|
| 2014 |
Chan SM, Thomas D, Medeiros BC, Majeti R. Isocitrate Dehydrogenase Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia through Inhibition of Cytochrome C Oxidase Function Blood. 124: 615-615. DOI: 10.1182/Blood.V124.21.615.615 |
0.671 |
|
| 2014 |
Jung N, Dai B, Gentles AJ, Murakami P, Majeti R, Feinberg AP. Epigenetic Signature of Leukemia Stem Cells Defines Subgroups Associated with Clinical Outcome and Cell of Origin in AML Blood. 124: 2147-2147. DOI: 10.1182/Blood.V124.21.2147.2147 |
0.453 |
|
| 2014 |
Thomas D, Sinha S, Gentles A, Jung N, Feinberg A, Dill D, Majeti R. Wilms' tumor 1 mutation drives DNA hypermethylation in AML and responds to EZH2-inhibitor Experimental Hematology. 42: S62. DOI: 10.1016/J.Exphem.2014.07.237 |
0.475 |
|
| 2014 |
Reinisch A, Majeti R. An in vivo model of primary myelofibrosis using a humanized bone marrow niche reveals disease-initiating cells enriched in the CD34+/CD38-/CD90+ hematopoietic compartment Experimental Hematology. 42: S18. DOI: 10.1016/J.Exphem.2014.07.064 |
0.721 |
|
| 2014 |
Majeti R. Clonal evolution of pre-leukemic hematopoietic stem cells in human acute myeloid leukemia Experimental Hematology. 42: S8. DOI: 10.1016/J.Exphem.2014.07.025 |
0.467 |
|
| 2013 |
Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. International Journal of Hematology. 98: 648-57. PMID 23949914 DOI: 10.1007/S12185-013-1407-8 |
0.639 |
|
| 2013 |
Huang M, Thomas D, Li MX, Feng W, Chan SM, Majeti R, Mitchell BS. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia. 27: 1970-80. PMID 23877794 DOI: 10.1038/Leu.2013.222 |
0.666 |
|
| 2013 |
McClellan JS, Majeti R. The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould. Embo Molecular Medicine. 5: 7-9. PMID 23229878 DOI: 10.1002/Emmm.201202207 |
0.482 |
|
| 2013 |
Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, Aztberger A, Schuh A, Grimwade D, Ivey A, Virgo P, Hills R, McSkeane T, Arrazi J, Knapper S, ... ... Majeti R, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia. 27: 1028-36. PMID 23223186 DOI: 10.1038/Leu.2012.312 |
0.491 |
|
| 2013 |
Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene. 32: 135-40. PMID 22349821 DOI: 10.1038/Onc.2012.48 |
0.737 |
|
| 2013 |
Chung S, Pang W, Jan M, Klimek V, Weissman I, Majeti R, Park C. CD99 identifies disease stem cells in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) Experimental Hematology. 41: S16. DOI: 10.1016/J.Exphem.2013.05.060 |
0.831 |
|
| 2012 |
Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, Majeti R. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Science Translational Medicine. 4: 149ra118. PMID 22932223 DOI: 10.1182/Blood.V126.23.Sci-11.Sci-11 |
0.773 |
|
| 2012 |
Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood. 119: 5492-501. PMID 22529286 DOI: 10.1182/Blood-2011-07-365890 |
0.555 |
|
| 2012 |
Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 109: 6656-61. PMID 22451919 DOI: 10.1073/Pnas.1121629109 |
0.769 |
|
| 2012 |
Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, ... ... Majeti R, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 109: 6662-7. PMID 22451913 DOI: 10.1073/Pnas.1121623109 |
0.82 |
|
| 2012 |
Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Current Opinion in Immunology. 24: 225-32. PMID 22310103 DOI: 10.1016/J.Coi.2012.01.010 |
0.742 |
|
| 2012 |
Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nature Reviews. Cancer. 12: 58-67. PMID 22158022 DOI: 10.1038/Nrc3171 |
0.722 |
|
| 2012 |
Ochsenreither S, Majeti R, Loeb K, Stirewalt DL, Keilholz U, Weissman IL, Greenberg PD. Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells. Journal of Clinical Oncology. 30: 2523-2523. DOI: 10.1200/Jco.2012.30.15_Suppl.2523 |
0.521 |
|
| 2012 |
Chao MP, Majeti R, Weissman I. Response: Mechanisms of targeting CD47-SIRPα in hematologic malignancies Blood. 119: 4334-4335. DOI: 10.1182/Blood-2012-02-411249 |
0.586 |
|
| 2012 |
Jan M, Snyder T, Corces-Zimmerman MR, Quake S, Weissman I, Majeti R. Abstract SY35-01: Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy35-01 |
0.775 |
|
| 2012 |
Jan M, Snyder TM, Corces-Zimmerman MR, Weissman IL, Quake SR, Majeti R. Abstract 3303: Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia Cancer Research. 72: 3303-3303. DOI: 10.1158/1538-7445.Am2012-3303 |
0.777 |
|
| 2011 |
Alizadeh AA, Majeti R. Surprise! HSC are aberrant in chronic lymphocytic leukemia. Cancer Cell. 20: 135-6. PMID 21840478 DOI: 10.1016/J.Ccr.2011.08.001 |
0.437 |
|
| 2011 |
Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 118: 4890-901. PMID 21828138 DOI: 10.1182/Blood-2011-02-338020 |
0.799 |
|
| 2011 |
Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proceedings of the National Academy of Sciences of the United States of America. 108: 5009-14. PMID 21383193 DOI: 10.1073/Pnas.1100551108 |
0.812 |
|
| 2011 |
Gibbs KD, Gilbert PM, Sachs K, Zhao F, Blau HM, Weissman IL, Nolan GP, Majeti R. Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments. Blood. 117: 4226-33. PMID 21357764 DOI: 10.1182/Blood-2010-07-298232 |
0.614 |
|
| 2011 |
Majeti R, Weissman IL. Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye. Cancer Cell. 19: 9-10. PMID 21251611 DOI: 10.1016/J.Ccr.2011.01.007 |
0.554 |
|
| 2011 |
Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Research. 71: 1374-84. PMID 21177380 DOI: 10.1158/0008-5472.Can-10-2238 |
0.841 |
|
| 2011 |
Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene. 30: 1009-19. PMID 21076471 DOI: 10.1038/Onc.2010.511 |
0.583 |
|
| 2011 |
Craddock CF, Goardon N, Quek L, Freeman S, Siddique S, Raghavan M, Schuh A, Grimwade D, Hills RK, Brookes C, Griffiths M, Cavenagh JD, Majeti R, Weissman IL, Burnett AK, et al. Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia Blood. 118: 638-638. DOI: 10.1182/Blood.V118.21.638.638 |
0.526 |
|
| 2011 |
Gentles AJ, Majeti R, Alizadeh AA. Leukemic stem cell gene expression signature and clinical outcomes in acute myeloid leukemia: Reply Jama - Journal of the American Medical Association. 305: 1094-1095. DOI: 10.1001/Jama.2011.300 |
0.386 |
|
| 2010 |
Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Science Translational Medicine. 2: 63ra94. PMID 21178137 DOI: 10.1126/Scitranslmed.3001375 |
0.838 |
|
| 2010 |
Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. Jama. 304: 2706-15. PMID 21177505 DOI: 10.1001/Jama.2010.1862 |
0.473 |
|
| 2010 |
Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, ... ... Majeti R, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142: 699-713. PMID 20813259 DOI: 10.1016/J.Cell.2010.07.044 |
0.817 |
|
| 2010 |
Diehn M, Majeti R. Metastatic cancer stem cells: an opportunity for improving cancer treatment? Cell Stem Cell. 6: 502-3. PMID 20569685 DOI: 10.1016/J.Stem.2010.05.001 |
0.407 |
|
| 2010 |
Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends in Immunology. 31: 212-9. PMID 20452821 DOI: 10.1016/J.It.2010.04.001 |
0.832 |
|
| 2010 |
Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, Majeti R, Kogel KE, Azar CA, Patel S, Alizadeh AA. Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Leukemia Research. 34: 594-7. PMID 19781775 DOI: 10.1016/J.Leukres.2009.08.029 |
0.437 |
|
| 2010 |
Chao MP, Alizadeh AA, Tang CZ, Myklebust JH, Varghese B, Jan M, Cha AC, Tan BT, Park CY, Levy R, Weissman IL, Majeti R. Abstract 2440: CD47 is a prognostic factor and an antibody target that synergizes with rituximab to eradicate non-Hodgkin lymphoma Cancer Research. 70: 2440-2440. DOI: 10.1158/1538-7445.Am10-2440 |
0.841 |
|
| 2009 |
Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 138: 286-99. PMID 19632179 DOI: 10.1016/J.Cell.2009.05.045 |
0.851 |
|
| 2009 |
Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 138: 271-85. PMID 19632178 DOI: 10.1016/J.Cell.2009.05.046 |
0.838 |
|
| 2009 |
Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R, Chiang JH, Hood L, Clarke MF, Weissman IL. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America. 106: 3396-401. PMID 19218430 DOI: 10.1073/Pnas.0900089106 |
0.563 |
|
| 2009 |
Ooi AG, Karsunky H, Majeti R, Butz S, Vestweber D, Ishida T, Quertermous T, Weissman IL, Forsberg EC. The adhesion molecule esam1 is a novel hematopoietic stem cell marker. Stem Cells (Dayton, Ohio). 27: 653-61. PMID 19074415 DOI: 10.1634/Stemcells.2008-0824 |
0.544 |
|
| 2009 |
Gibbs K, Gilbert P, Weissman IL, Blau HM, Nolan GP, Majeti R. Single Cell Phospho-Flow Analysis of Cytokine Stimulation in Human Hematopoietic Progenitors Reveals That G-CSF Acts Directly On Human Hematopoietic Stem Cells. Blood. 114: 3617-3617. DOI: 10.1182/Blood.V114.22.3617.3617 |
0.538 |
|
| 2009 |
Chao MP, Alizadeh AA, Tang CZ, Myklebust JH, Varghese B, Jan M, Levy R, Weissman IL, Majeti R. Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts. Blood. 114: 2716-2716. DOI: 10.1182/Blood.V114.22.2716.2716 |
0.821 |
|
| 2009 |
Kohrt HE, Patel S, Ho M, Owen T, Majeti R, Gotlib JR, Coutre S, Medeiros BC, Alizadeh AA. Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). Blood. 114: 1617-1617. DOI: 10.1182/Blood.V114.22.1617.1617 |
0.301 |
|
| 2009 |
Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, Weissman IL. Abstract CN07-03: CD47 is an adverse prognostic factor and therapeutic antibody target on human AML stem cells Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-Cn07-03 |
0.857 |
|
| 2008 |
Park CY, Majeti R, Weissman IL. In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood. Nature Protocols. 3: 1932-40. PMID 19180077 DOI: 10.1038/Nprot.2008.194 |
0.692 |
|
| 2008 |
Majeti R, Chao MP, Alizadeh AA, Pang WW, Weissman IL. CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells Blood. 112: 766-766. DOI: 10.1182/Blood.V112.11.766.766 |
0.818 |
|
| 2007 |
Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 1: 635-45. PMID 18371405 DOI: 10.1016/j.stem.2007.10.001 |
0.722 |
|
| 2006 |
Park CY, Majeti R, Tan BT, Weissman IL. Development of a Novel Xenotransplantation System for Studying Human Acute Myeloid Leukemia. Blood. 108: 1947-1947. DOI: 10.1182/Blood.V108.11.1947.1947 |
0.735 |
|
| 2005 |
Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity. 23: 635-47. PMID 16356861 DOI: 10.1016/J.Immuni.2005.11.001 |
0.688 |
|
| 2002 |
Hermiston ML, Xu Z, Majeti R, Weiss A. Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. The Journal of Clinical Investigation. 109: 9-14. PMID 11781344 DOI: 10.1172/Jci14794 |
0.565 |
|
| 2001 |
Majeti R, Weiss A. Regulatory mechanisms for receptor protein tyrosine phosphatases. Chemical Reviews. 101: 2441-8. PMID 11749382 DOI: 10.1021/Cr000085M |
0.423 |
|
| 2001 |
Baker JE, Majeti R, Tangye SG, Weiss A. Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase Cgamma1 phosphorylation. Molecular and Cellular Biology. 21: 2393-403. PMID 11259588 DOI: 10.1128/Mcb.21.7.2393-2403.2001 |
0.597 |
|
| 2000 |
Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, Weiss A. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell. 103: 1059-70. PMID 11163182 DOI: 10.1016/S0092-8674(00)00209-9 |
0.667 |
|
| 1999 |
Lagunoff M, Majeti R, Weiss A, Ganem D. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Proceedings of the National Academy of Sciences of the United States of America. 96: 5704-9. PMID 10318948 DOI: 10.1073/Pnas.96.10.5704 |
0.46 |
|
| 1998 |
Majeti R, Bilwes AM, Noel JP, Hunter T, Weiss A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science (New York, N.Y.). 279: 88-91. PMID 9417031 DOI: 10.1126/Science.279.5347.88 |
0.562 |
|
| Show low-probability matches. |